| May your drug price be evergreen R Feldman Journal of Law and the Biosciences 5 (3), 590-647, 2018 | 193 | 2018 |
| The insufficiency of antitrust analysis for patent misuse RC Feldman Hastings LJ 55, 399, 2003 | 170 | 2003 |
| Defensive leveraging in antitrust RC Feldman Geo. LJ 87, 2079, 1998 | 146 | 1998 |
| The role of science in law R Feldman Oxford University Press, 2009 | 144 | 2009 |
| The America Invents Act 500: Effects of patent monetization entities on US litigation S Jeruss, R Feldman, J Walker Duke L. & Tech. Rev. 11, 357, 2012 | 136 | 2012 |
| The open source biotechnology movement: Is it patent misuse? R Feldman Minn. JL Sci. & Tech. 6, 117, 2004 | 128 | 2004 |
| Do patent licensing demands mean innovation R Feldman, MA Lemley Iowa L. Rev. 101, 137, 2015 | 115 | 2015 |
| Copyright and open access at the bedside. JC Newman, R Feldman The New England journal of medicine 365 (26), 2447-2449, 2011 | 109 | 2011 |
| Rethinking Rights in Biospace R Feldman S. Cal. l. rev. 79, 1, 2005 | 81 | 2005 |
| The giants among us R Feldman, T Ewing Stanford Technology Law Review 2012, 1, 2012 | 78 | 2012 |
| Patent licensing, technology transfer, and innovation MA Lemley, R Feldman American Economic Review 106 (5), 188-192, 2016 | 75 | 2016 |
| Patent demands & startup companies: The view from the venture capital community R Feldman Yale JL & Tech. 16, 236, 2013 | 75 | 2013 |
| Drug wars: A new generation of generic pharmaceutical delay R Feldman, E Frondorf Harv. J. on Legis. 53, 499, 2016 | 72 | 2016 |
| Regulatory property: the new IP R Feldman Colum. JL & Arts 40, 53, 2016 | 70 | 2016 |
| Artificial intelligence in the health care space: how we can trust what we cannot know RC Feldman, E Aldana, K Stein Stan. L. & Pol'y Rev. 30, 399, 2019 | 68 | 2019 |
| The AIA 500 Expanded: The Effects of Patent Monetization Entities R Feldman, T Ewing, S Jeruss UC Hastings Research Paper, 2013 | 66 | 2013 |
| Intellectual Property Wrongs R Feldman Stan. JL Bus. & Fin. 18, 250, 2012 | 61 | 2012 |
| Considerations on the emerging implementation of biometric technology R Feldman Hastings Comm. & Ent. LJ 25, 653, 2002 | 58 | 2002 |
| Patent and antitrust: Differing shades of meaning R Feldman Va. JL & Tech. 13, 1, 2008 | 56 | 2008 |
| Patent Trolling: Why Bio & Pharmaceuticals Are at Risk R Feldman, W Price, II Nicholson Stan. Tech. L. Rev. 17, 773, 2013 | 55 | 2013 |
Mark LemleyProfessor of Law, Stanford University在 law.stanford.edu 的电子邮件经过验证
Mark LemleyProfessor of Law, Stanford University在 law.stanford.edu 的电子邮件经过验证